• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Mepolizumab reduced exacerbations in children with exacerbation-prone eosinophilic asthma

byJessie WillisandTeddy Guo
August 24, 2022
in Chronic Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. There was a 27% reduction of severe asthma exacerbations in children treated with mepolizumab compared to control.

2. There were more frequent adverse events in the treatment group; however, these were mostly injection site reactions and there were no treatment-related deaths.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Asthma is responsible for 1.3 million emergency room visits per year in the United States. Proper asthma control is integral to preventing serious acute exacerbations. The use of a biologic therapy, mepolizumab, has been shown to reduce exacerbations in an adult population. This study aimed to evaluate the use of mepolizumab in racially and ethnically diverse pediatric populations. Participants were randomized 1:1 to either placebo or mepolizumab, both given as a subcutaneous injection every four weeks for 52 weeks. In the 52-week treatment period, there was a 27% rate reduction of severe exacerbations in the treatment group compared to the control. Adverse events occurred in one-third of the treatment group compared to one-tenth in the control group, with the most common being injection site reactions in both groups. There were no deaths associated with treatment. Limitations to the study include lack of follow-up post-treatment. Nevertheless, this study demonstrated the effectiveness of the use of mepolizumab at reducing asthma exacerbations in children. Additionally, there was an overall decrease in exacerbations in the placebo group, indicating the importance of consistent follow-up and guideline-based care for these children.

Click to read the study in the Lancet

Relevant Reading: Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

In-Depth [randomized control trial]: The MUPPITS-2 study is a randomized control trial that ran in nine medical centres in the USA. Participants were enrolled through a recruitment questionnaire and were eligible if they were aged 6-17 years old with asthma for at least one year with two or more exacerbations treated with systemic corticosteroids and managed on an inhaled corticosteroid at baseline. Included participants had to live in low-income US census tracts. A total of 290 participants were randomized 1:1 to either mepolizumab (n = 146) or placebo (n = 144) and were included in the intention-to-treat analysis. Treatment with mepolizumab was in the form of a subcutaneous injection once every 4 weeks for a total of 52 weeks. The primary outcome was the recorded number of asthma exacerbations that required treatment with systemic corticosteroids within 52 weeks. The mean number of asthma exacerbations was 0.96 (95% CI 0.78-1.17) in the mepolizumab group and 1.30 (1.08-1.57) in the placebo group (RR 0.73, 0.56-0.96, p = 0.027). Adverse events occurred in 29% of the treatment group compared to 11% of the placebo. The most common adverse events were injection site reactions in both groups. One death occurred in the mepolizumab group, but this was related to an acute asthma exacerbation and not study treatment.

RELATED REPORTS

Emergency department crowding negative influences outcomes for adults presenting with asthma

The Scan by 2 Minute Medicine®: Overprescribed and Understocked, A Costly Message, A Bad Wrap and Mauna Loa Erupts Again!

  Vitamin C supplementation in pregnancy improves respiratory function in children of smoking mothers at 5 years of age

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: asthmaasthma exacerbationeosinophiliaMepolizumabpulmonary function testpulmonologyrespirology
Previous Post

Left atrial appendage occlusion is an effective alternative to oral anticoagulation in atrial fibrillation

Next Post

Prehospital needle decompression associated with decreased mortality in trauma patients

RelatedReports

Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Emergency

Emergency department crowding negative influences outcomes for adults presenting with asthma

December 27, 2022
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Overprescribed and Understocked, A Costly Message, A Bad Wrap and Mauna Loa Erupts Again!

December 14, 2022
Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity
Chronic Disease

  Vitamin C supplementation in pregnancy improves respiratory function in children of smoking mothers at 5 years of age

December 7, 2022
Postextubation administration of high-flow oxygen leads to reduced reintubation and respiratory failure
Emergency

Pressure support ventilation does not improve ventilation status as compared to T-piece ventilation

November 18, 2022
Next Post
Steroids and opioids often inappropriately prescribed in the emergency department for pediatric pneumonia and sinusitis

Prehospital needle decompression associated with decreased mortality in trauma patients

#VisualAbstract: Removal of asymptomatic kidney stones reduces risk of relapse

#VisualAbstract: Provision of 1-year mortality data for patients hospitalized with heart failure does not influence clinical decision-making – The REVEAL-HF trial

Palliative care consultation linked to lower deaths by failed code resuscitation

Wellness Check: Spirituality

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options